Orphan drug legislation
Senate Labor & Human Resources Committee could schedule a markup as soon as this month on S 2060, Sens. Metzenbaum (D-Ohio) and Kassebaum's (R-Kan.) bill to set a $200 mil. sales "trigger" on orphan drugs. Once the trigger is reached, FDA could consider competitor marketing applications during a product's exclusivity period. Committee Chairman Kennedy (D-Mass.) also is looking seriously at "windfall" profits tax approaches to address concerns about big-selling orphan drugs.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth